Value
7.1/10data confidence 83%| Component | Sub-score |
|---|---|
| P/E | 7.4 |
| P/S | 8.3 |
| EV/EBITDA | 5.5 |
| Fwd P/E | 9.3 |
| Analyst target | 5.0 |
- ▸Forward P/E: 9.8x
- ▸Attractively valued
GSK · Why this verdict
Why GSK (GSK) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.4/10
ConfidenceMEDIUM
MacroRISK_OFF
TrendMatrix Research · core thesis
Engine thesis — one sentence
GSK is a high-quality pharmaceutical franchise with an impressive four-quarter earnings beat streak and strong profitability, but the stock has reached its near-term price ceiling with only 0.3% of headroom remaining and an unfavorable risk/reward, making patience the appropriate posture for existing holders while dividend sustainability warrants monitoring.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Return on equity of 41%, operating margins of 18%, and a Piotroski financial health score of 7 out of 9 mark this as a high-quality pharmaceutical franchise with durable profitability characteristics well above the peer average. Quality breakdown | Over 12 months, operating margins remain at or above 15%, confirming the profitability is structural rather than cyclical. | ↑Improving |
| CounterFree cash flow conversion stands at only 52% of net income — meaning less than half of reported earnings translates to cash — raising a quality concern about whether the headline profitability is as durable as the margin metrics suggest. | ||
With only 0.3% of headroom between the current price and the near-term target and an unfavorable risk/reward, the stock offers virtually no margin of safety for new entry, making initiating a position imprudent at current levels despite the quality of the underlying business. Price targets | If this pillar proves wrong, analyst price target upgrades driven by continued earnings momentum push the consensus target more than 10% above $52.23, restoring a meaningful risk/reward cushion. | →Stable |
| CounterAt a forward price-to-earnings of 10 times, the stock screens inexpensive relative to its 41% return on equity; a re-rating toward a market-rate pharmaceutical multiple could unlock additional appreciation without any fundamental improvement. | ||
GSK has beaten consensus earnings estimates in each of the past four quarters, with an average positive surprise of approximately 11.7%, reflecting a management team that has consistently delivered more than the analyst community anticipated. Earnings | Over 12 months, the company delivers at least two additional quarterly earnings beats, sustaining the pattern of positive surprises. | →Stable |
| CounterFour consecutive beats can reflect a period of artificially low consensus expectations rather than genuine outperformance; if analysts reset estimates upward ahead of upcoming prints, the room for further positive surprises narrows materially. | ||
Despite a high nominal yield, the payout has been flagged as potentially unsafe, which could impair the income thesis supporting a portion of the shareholder base if the dividend is reduced. Catalyst breakdown | If this pillar proves wrong, free cash flow conversion rises above 80% of net income for two consecutive quarters, removing the sustainability concern. | →Stable |
| CounterManagement at pharmaceutical businesses with predictable revenue streams often prioritizes dividend consistency; the payout can persist through a period of suboptimal cash conversion if the company is willing to temporarily absorb balance sheet pressure. | ||
Return on equity of 41%, operating margins of 18%, and a Piotroski financial health score of 7 out of 9 mark this as a high-quality pharmaceutical franchise with durable profitability characteristics well above the peer average.
↑ImprovingQuality breakdown
- Expectation
- Over 12 months, operating margins remain at or above 15%, confirming the profitability is structural rather than cyclical.
CounterFree cash flow conversion stands at only 52% of net income — meaning less than half of reported earnings translates to cash — raising a quality concern about whether the headline profitability is as durable as the margin metrics suggest.
With only 0.3% of headroom between the current price and the near-term target and an unfavorable risk/reward, the stock offers virtually no margin of safety for new entry, making initiating a position imprudent at current levels despite the quality of the underlying business.
→StablePrice targets
- Expectation
- If this pillar proves wrong, analyst price target upgrades driven by continued earnings momentum push the consensus target more than 10% above $52.23, restoring a meaningful risk/reward cushion.
CounterAt a forward price-to-earnings of 10 times, the stock screens inexpensive relative to its 41% return on equity; a re-rating toward a market-rate pharmaceutical multiple could unlock additional appreciation without any fundamental improvement.
GSK has beaten consensus earnings estimates in each of the past four quarters, with an average positive surprise of approximately 11.7%, reflecting a management team that has consistently delivered more than the analyst community anticipated.
→StableEarnings
- Expectation
- Over 12 months, the company delivers at least two additional quarterly earnings beats, sustaining the pattern of positive surprises.
CounterFour consecutive beats can reflect a period of artificially low consensus expectations rather than genuine outperformance; if analysts reset estimates upward ahead of upcoming prints, the room for further positive surprises narrows materially.
Despite a high nominal yield, the payout has been flagged as potentially unsafe, which could impair the income thesis supporting a portion of the shareholder base if the dividend is reduced.
→StableCatalyst breakdown
- Expectation
- If this pillar proves wrong, free cash flow conversion rises above 80% of net income for two consecutive quarters, removing the sustainability concern.
CounterManagement at pharmaceutical businesses with predictable revenue streams often prioritizes dividend consistency; the payout can persist through a period of suboptimal cash conversion if the company is willing to temporarily absorb balance sheet pressure.
Per-dimension breakdown
Quality
7.1/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 9.4 |
| ROA | 6.2 |
| Gross margin | 10.0 |
| Op margin | 10.0 |
| Net margin | 6.5 |
| Current ratio | 3.5 |
| FCF quality | 9.1 |
| Moat | 6.4 |
| Rule of 40 | 3.0 |
| Piotroski F | 6.7 |
- ▸Excellent ROE: 28%
- ▸Excellent cash conversion: 122% FCF/NI
- ▸Rule of 40: 20 (fail)
Growth
1.8/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 3.5 |
| EPS growth | 0.0 |
Momentum
6.2/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.5 |
| MACD | 8.1 |
| OBV | 10.0 |
| MA position | 7.2 |
| Volume | 1.1 |
- ▸Volume accumulation (rising OBV)
- ▸Below 200-MA but MA still rising (+0.3%/30d) — pullback in uptrend, not confirmed weakness
Sentiment
6.1/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 6.4 |
| Analyst rating | 5.0 |
| Price target | 7.2 |
Insider
5.0/10data confidence 50%Peer rank
4.3/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 6.5 |
| quality rank | 5.4 |
| growth rank | 2.5 |
Technical
3.4/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 1.9 |
| support resistance | 0.5 |
| 52w position | 7.0 |
| gap | 4.0 |
Risk (lower is worse)
6.6/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 9.6 |
| days to cover | 7.9 |
| volatility | 6.3 |
| put call | 5.8 |
| implied vol | 5.6 |
| max pain risk | 3.0 |
| beta | 10.0 |
| debt equity | 4.4 |
- ▸Above max pain $42
Catalyst
6.5/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 7.1 |
| dividend safety | 4.2 |
| news activity | 8.0 |
- ▸Perfect beat streak: 4Q
- ▸Dividend: 3.7%
How the verdict was assembled
Engine trigger
Multiple concerning factors. Consider reducing position.
Engine technical detail
verdict_path:
L4:PATH_F_SELLPassed (6)
- MOMENTUM:6.2>=5.5
- INSIDER:OK
- 8K:CLEAN
- EARNINGS_PROXIMITY:91d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:0.1<1.5@spot
Warning (0)
none
Reward-to-Risk
0.05
Upside
+0.6%
Downside
10.4%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilityModerate — Balanced profile
Investment implication
The F-path SELL output reflects an overall score of 5.6 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. The strongest dimension ( Value at 7.1) was not enough to lift the adjusted overall above the threshold. Co-occurring failed gates ( ASYMMETRY:0.1<1.5@spot) reinforce the read. Current asymmetry R:R is 0.05 — supplementary context, not the trigger for this path.
The strongest dimensions are Value at 7.1, Quality at 7.1, and Risk (lower is worse) at 6.6; the weakest are Growth at 1.8, Technical at 3.4, and Peer rank at 4.3. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of 0.05 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Consistent Earnings Outperformance
Trip ifEPS surprise falls below 0% for 2 consecutive quarters.
- P2High Quality Franchise Profitability
Trip ifOperating margin compresses below 15% for 2 consecutive quarters.
- P3Valuation At Price Ceiling
Trip ifAnalyst consensus price target rises more than 10% above $52.23, restoring a meaningful cushion.
- P4Dividend Sustainability Concern
Trip ifFree cash flow conversion rises above 80% of net income for 2 consecutive quarters.